PHAT vs. IGMS, CALT, AVBP, STOK, AVTE, GHRS, OLMA, CDMO, ZYME, and PHAR
Should you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include IGM Biosciences (IGMS), Calliditas Therapeutics AB (publ) (CALT), ArriVent BioPharma (AVBP), Stoke Therapeutics (STOK), Aerovate Therapeutics (AVTE), GH Research (GHRS), Olema Pharmaceuticals (OLMA), Avid Bioservices (CDMO), Zymeworks (ZYME), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical preparations" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.
Phathom Pharmaceuticals presently has a consensus price target of $22.00, indicating a potential upside of 124.95%. IGM Biosciences has a consensus price target of $17.89, indicating a potential upside of 81.98%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Phathom Pharmaceuticals is more favorable than IGM Biosciences.
Phathom Pharmaceuticals has higher earnings, but lower revenue than IGM Biosciences. IGM Biosciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phathom Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
In the previous week, Phathom Pharmaceuticals and Phathom Pharmaceuticals both had 14 articles in the media. Phathom Pharmaceuticals' average media sentiment score of 0.73 beat IGM Biosciences' score of 0.30 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.
99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 56.9% of IGM Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Phathom Pharmaceuticals has a net margin of 0.00% compared to IGM Biosciences' net margin of -11,255.25%. Phathom Pharmaceuticals' return on equity of 0.00% beat IGM Biosciences' return on equity.
Phathom Pharmaceuticals received 5 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 67.33% of users gave Phathom Pharmaceuticals an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
Summary
Phathom Pharmaceuticals beats IGM Biosciences on 12 of the 17 factors compared between the two stocks.
Get Phathom Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phathom Pharmaceuticals Competitors List
Related Companies and Tools
